Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves'

Status Completed

Clinical Trial Summary

The purpose of the present interventional study is to assess the changes in the therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy. The main questions it aim to answer are: 1. How effective is orbital radiotherapy used as first- or second-line treatment in patients with Graves' orbitopathy? 2. How does the quality of life changes after orbital radiotherapy? Participants have active moderate-to-severe Graves' orbitopathy and are treated with low dose fractionated orbital radiotherapy for two weeks. During the follow-up period they undergo regular ocular examinations and fill out a disease-specific questionnaire.

Clinical Trial Description

Orbital radiotherapy is a well-established second-line therapy for moderate-to-severe forms of Graves' orbitopathy. However, the question about it efficacy is still controversial. The purpose of the present interventional study is to assess the changes in the therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy. The main questions it aim to answer are: 1. How effective is orbital radiotherapy used as first- or second-line treatment in patients with Graves' orbitopathy? 2. How does the quality of life changes after orbital radiotherapy? Participants have active moderate-to-severe Graves' orbitopathy untreated or already treated with systemic glucocorticoids and are referred to low dose fractionated orbital radiotherapy, total dose 20 Gy divided into 10 sessions, 2 Gy for each session. A concomitant intake of low-dose glucocorticoids is prescribed to all patient. During the follow-up period they undergo regular ocular examinations (at 1st, 3rd, 6th and 12th month), which includes comprehensive ocular status, hormonal and immunological testing and evaluation of the current therapeutic response. The patients also fill out a disease-specific questionnaire (at 3rd, 6th and 12th months). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05775185
Study type	Observational [Patient Registry]
Source	Medical University of Sofia
Contact
Status	Completed
Phase
Start date	July 25, 2017
Completion date	February 25, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05532072` - Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.	Early Phase 1
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05678374` - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Recruiting	`NCT03708627` - Bimatoprost as a Treatment for Graves' Orbitopathy	Early Phase 1
Withdrawn	`NCT01379196` - Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy	Phase 1/Phase 2
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting	`NCT06226545` - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease	Phase 2
Recruiting	`NCT05126147` - Hydroxychloroquine in Mild Graves' Orbitopathy	Phase 4
Recruiting	`NCT01999790` - Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy	N/A
Recruiting	`NCT03066076` - Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy	Phase 3
Active, not recruiting	`NCT03122847` - Glucocorticoids and Bone in Graves' Ophthalmopathy
Terminated	`NCT01893450` - Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment	N/A
Completed	`NCT00348413` - Thyroid Treatment Trial	N/A
Completed	`NCT03498417` - Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
Not yet recruiting	`NCT04598815` - Sirolimus for Graves' Orbitopathy (GO)	Phase 2
Terminated	`NCT01114503` - A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease	Phase 2
Completed	`NCT05793359` - Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
Recruiting	`NCT02203682` - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy	Phase 2
Recruiting	`NCT05276063` - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms